MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-31-2025
Laboratory Corporation of America Holdings Book Value 2011-2026 | LH
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Laboratory Corporation of America Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.07 B | 7.89 B | 10.1 B | 10.3 B | 9.36 B | 7.57 B | 6.97 B | 6.83 B | 5.51 B | 4.94 B | 2.82 B | 2.49 B | 2.72 B | 2.52 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.3 B | 2.49 B | 6.29 B |
Quarterly Book Value Laboratory Corporation of America Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.71 B | 8.49 B | 8.32 B | 8.07 B | 8.19 B | 8.02 B | 7.97 B | 7.89 B | 7.89 B | 8.8 B | 10.4 B | 10.1 B | 10.1 B | - | 10.7 B | 10.3 B | 10.5 B | 10.3 B | 10 B | 9.46 B | 9.38 B | 9.38 B | 9.38 B | 7.59 B | 7.59 B | 7.59 B | 7.59 B | 6.99 B | 6.99 B | 6.99 B | 6.99 B | 6.82 B | 6.82 B | 6.82 B | 6.82 B | 5.52 B | 5.52 B | 5.52 B | 5.52 B | 4.96 B | 4.88 B | 4.88 B | 4.88 B | 2.84 B | 2.84 B | 2.84 B | 2.84 B | 2.51 B | 2.51 B | 2.51 B | 2.51 B | 2.74 B | 2.74 B | 2.74 B | 2.74 B | 2.52 B | 2.52 B | 2.52 B | 2.52 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 10.7 B | 2.51 B | 6.42 B |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
75.7 M | $ 23.39 | 5.79 % | $ 99.4 M |  Israel |
 |
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
1.85 B | $ 22.72 | 1.59 % | $ 246 M |  China |
 |
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
BioNano Genomics
BNGO
|
35.4 M | $ 1.6 | - | $ 2.03 M | USA |
 |
Castle Biosciences
CSTL
|
456 M | $ 40.03 | -1.43 % | $ 1.11 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M |  Britain |
 |
Co-Diagnostics
CODX
|
86 M | $ 6.05 | 0.33 % | $ 178 M | USA |
 |
DarioHealth Corp.
DRIO
|
96.4 M | $ 12.31 | 1.52 % | $ 349 M | Israel |
 |
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | USA |
 |
Fulgent Genetics
FLGT
|
1.13 B | $ 27.91 | -0.36 % | $ 844 M | USA |
 |
Danaher Corporation
DHR
|
77.5 B | $ 236.45 | 0.37 % | $ 173 B | USA |
 |
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | China |
 |
DexCom
DXCM
|
2.07 B | $ 67.5 | -3.71 % | $ 26.1 B | USA |
 |
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | China |
 |
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | USA |
 |
Exact Sciences Corporation
EXAS
|
2.4 B | $ 101.75 | 0.11 % | $ 18.9 B | USA |
 |
CareDx, Inc
CDNA
|
261 M | $ 17.67 | -6.51 % | $ 950 M | USA |
 |
Celcuity
CELC
|
116 M | $ 106.33 | -2.61 % | $ 4.19 B | USA |
 |
Anixa Biosciences
ANIX
|
18.9 M | $ 3.32 | 1.22 % | $ 106 K | USA |
 |
Guardant Health
GH
|
-140 M | $ 109.37 | -0.51 % | $ 13.4 B | USA |
 |
Aspira Women's Health
AWH
|
6.73 M | - | -6.19 % | $ 10.5 M | USA |
 |
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | USA |
 |
IQVIA Holdings
IQV
|
6.07 B | $ 243.24 | -0.43 % | $ 44.1 B | USA |
 |
Illumina
ILMN
|
6.3 B | $ 147.43 | -1.81 % | $ 23.4 B | USA |
 |
Charles River Laboratories International
CRL
|
3.51 B | $ 216.58 | -0.32 % | $ 11.1 B | USA |
 |
Mettler-Toledo International
MTD
|
-127 M | $ 1 476.11 | 0.4 % | $ 31.3 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
701 M | $ 6.51 | -1.89 % | $ 590 M | USA |
 |
National Research Corporation
NRC
|
49 M | $ 19.34 | 2.33 % | $ 475 M | USA |
 |
Natera
NTRA
|
706 M | $ 238.34 | -6.31 % | $ 23.5 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 177.53 | -0.38 % | $ 19.7 B | USA |
|
Biodesix
BDSX
|
20.9 M | $ 5.85 | -1.85 % | $ 759 M | USA |
 |
OPKO Health
OPK
|
1.37 B | $ 1.36 | -0.37 % | $ 944 M | USA |
 |
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | Israel |
 |
ICON Public Limited Company
ICLR
|
9.52 B | $ 189.24 | -6.74 % | $ 15.6 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.6 B | $ 706.32 | -1.15 % | $ 58.2 B | USA |
 |
Lantheus Holdings
LNTH
|
1.09 B | $ 69.55 | 0.26 % | $ 4.81 B | USA |
 |
Agilent Technologies
A
|
5.39 B | $ 146.93 | -0.59 % | $ 44.7 B | USA |
 |
Biomerica
BMRA
|
4.1 M | $ 2.79 | 0.36 % | $ 6.41 M | USA |
 |
Bioventus
BVS
|
221 M | $ 7.77 | 2.04 % | $ 487 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M | Israel |
 |
Koninklijke Philips N.V.
PHG
|
12 B | $ 29.53 | 1.46 % | $ 20 B |  Niderland |